EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jan H,Frenking

第一单位： Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany jan.frenking@med.uni-heidelberg.de.;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany.

作者： Jan H,Frenking ^[1] ; Xiang,Zhou ^[2] ; Vivien,Wagner ^[2] ; Thomas,Hielscher ^[3] ; Joseph,Kauer ^[4] ; Elias K,Mai ^[5] ; Mirco J,Friedrich ^[6] ; Christian S,Michel ^[5] ; Marina,Hajiyianni ^[5] ; Iris,Breitkreutz ^[5] ; Patrick,Costello ^[7] ; Omar,Nadeem ^[7] ; Niels,Weinhold ^[8] ; Hartmut,Goldschmidt ^[9] ; Anita,Schmitt ^[5] ; Thomas,Luft ^[5] ; Michael,Schmitt ^[5] ; Carsten,Müller-Tidow ^[9] ; Max,Topp ^[2] ; Hermann,Einsele ^[2] ; Peter,Dreger ^[5] ; Nikhil C,Munshi ^[7] ; Adam S,Sperling ^[10] ; Leo,Rasche ^[2] ; Sandra,Sauer ^[5] ; Marc S,Raab ^[8]

作者单位： Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany jan.frenking@med.uni-heidelberg.de.;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany. ^[1] Internal Medicine II, University Hospital of Würzburg, Würzburg, Bayern, Germany. ^[2] Division of Biostatistics, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany. ^[3] Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany.;Molecular Medicine Partnership Unit, Heidelberg, Baden-Württemberg, Germany. ^[4] Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany. ^[5] Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany.;Eli and Edythe L Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. ^[6] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ^[7] Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany.;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany. ^[8] Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-Württemberg, Germany.;National Center for Tumor Diseases, Heidelberg, Baden-Württemberg, Germany. ^[9] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA. ^[10]

关键词 chimeric antigen receptor - CAR cytopenia immunotherapy multiple myeloma treatment related adverse event - trAE

主题词人类(Humans);多发性骨髓瘤(Multiple Myeloma);男(雄)性(Male);女(雌)性(Female);中年人(Middle Aged);免疫疗法, 过继(Immunotherapy, Adoptive);老年人(Aged);回顾性研究(Retrospective Studies);成年人(Adult);危险性评估(Risk Assessment);生物制品(Biological Products);治疗结果(Treatment Outcome)

DOI 10.1136/jitc-2024-009220

PMID 39379098

发布时间 2025-03-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal for immunotherapy of cancer

2024年12卷10期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

Journal for immunotherapy of cancer

相似文献

Journal for immunotherapy of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

Journal for immunotherapy of cancer

相似文献

Journal for immunotherapy of cancer

相关期刊

检索历史清除